Drugs / Altropane (123I) Injection
Altropane (123I) Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05636852 | Apr 2023 → Jun 2024 | Parkinson disease, movement disorder | GE Healthcare | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Altropane (123I) Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05636852 ↗ |
| Modality | Diagnostic / imaging agent | “SPECT Brain Imaging” NCT05636852 ↗ |
| Route | Intravenous | “single intravenous (IV) administration” NCT05636852 ↗ |